Neuropathix with Chairman & CEO Dean Petkanas

Neuropathix

Neuropathix with Chairman & CEO Dean Petkanas today on Concierge For Better Living with Doc Rob only on The Cannabis Radio. Neuropathix is a biopharmaceutical company focused on the research and development of a pipeline of next-generation socially responsible pain management therapeutics to treat patients with significant unmet medical needs.

Dean Petkanas is a corporate finance and executive management professional with over 25 years of investment banking and capital markets experience.

In 2010 Mr. Petkanas co-founded Kannalife Sciences, Inc. and for the past 10 years was principally responsible for the creation and execution of the Company’s business model, including the licensing of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” from the National Institutes of Health for disease indications Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). In 2013, he was responsible for securing Series A financing for Kannalife.

Mr. Petkanas is a co-inventor of two US Patents, first in U.S. Patent #9611213 titled “Functionalized 1,3 Benzene-diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”

This patent is part of a divisional patent application by the Company to the USPTO whereby the Company sought separate claims for the composition of matter, covered in Pat. #9611213 and separate claims for a method of treatment in U.S. Patent #10004722 titled “Method for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediate Stress and Oxidative Stress with Novel Functionalized 1,3 Benzene-diols.”